Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Boehringer Ingelheim
Biotech
Boehringer digs in on ADCs with $991M AimedBio licensing accord
After charting several related moves earlier this year, Boehringer Ingelheim is returning to the antibody-drug conjugate well.
Fraiser Kansteiner
Oct 15, 2025 10:05am
Boehringer, Click DTx hits phase 3 goal in schizophrenia
Oct 14, 2025 12:08pm
FDA considers new liver trial endpoint, sending MASH shares up
Aug 28, 2025 11:25am
Boehringer inks another eye disease deal, this time with Palatin
Aug 18, 2025 10:30am
Boehringer pens $1B pact to reduce eye drug injections
Jul 28, 2025 8:48am
Boehringer 'crossing fingers' ahead of 2 key FDA approvals
Jul 24, 2025 3:00am
